SCOLR Pharma Announces Completion Of Patient Enrollment And Dosing For Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
SCOLR Pharma, Inc. (Amex: DDD) announced the completion of patient enrollment and dosing for the third of its three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to report top-line results from this pivotal trial in November 2008.
Mail this post 
Health is the Most Precious Asset to us! Just willing to share with you what I have learned from Nutriotional Immunology.
